Ibrahim Komeil
☆    

Egypt,
2019-11-18 10:03
(1592 d 00:41 ago)

Posting: # 20818
Views: 1,239
 

 Furosemide oral tablet [Regulatives / Guidelines]

Dear all

I would like to ask about bioequivalence study for Furosemide oral tablet. It is listed in FDA draft guidance that it is not high variable drug and i can use 2 way crossover design. However, i read EMA guidelines and MHRA guidelines assure its high interasubject variability so they recommend to have partial replicated design applying normal acceptance range (80%-125%), so what do you think about these data upon on your experience ?
UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,639 registered users;
84 visitors (0 registered, 84 guests [including 7 identified bots]).
Forum time: 10:44 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5